Clinical efficacy of polymyxin B in combination with tigecycline in pneumonia caused by pan-drug resistant Klebsiella pneumoniae / 国际生物医学工程杂志

Objective:To investigate the clinical efficacy of injectable polymyxin B combined with tigecycline in pneumonia caused by pan-drug resistant Klebsiella pneumonia (PDR-KP). Methods:The retrospective analysis utilized clinical data of 71 patients with PDR-KP admitted to the Neurointensive Care Unit of Beijing Chaoyang Integrative Medicine Emergency Medical Center between September 2018 and August 2021. All patients received injectable polymyxin B combined with tigecycline. The response rate, bacterial clearance rate, and safety of this therapeutic option were evaluated according to the clinical symptoms and biochemical parameters before treatment (baseline), 7 days after the treatment, and at the end of the treatment.Results:The treatment time of 71 patients ranged from 8 to 14 days, with an average of 11 days. The symptoms, signs, laboratory tests, and chest CT findings of most patients significantly improved after the treatment using polymyxin B combined with tigecycline. On the 7th day after the treatment, 37 patients were clinically effective, with a total effective rate of 52.1%(37/71); 41 patients obtained bacteriological clearance, with a bacterial clearance rate of 57.7%(41/71). At the end of treatment, 51 patients were clinically effective, with a total effective rate of 71.8%(51/71); 56 patients obtained bacteriological clearance, with a bacterial clearance rate of 78.9%(56/71). Compared with the results on the 7th day after the treatment, the total effective rate ( χ2=5.86, P=0.016) and bacterial clearance rate ( χ2=7.32, P=0.007) of patients at the end of treatment were significantly increased. Skin pigmentation occurred in 39.4%(28/71) of patients during the treatment. Conclusions:Polymyxin B combined with tigecycline can be tried as a treatment option for pneumonia caused by PDR-KP, but more reliable clinical evidence is still needed.

Multidrug resistant, extensively drug resistant and pan drug resistant gram negative bacteria at a tertiary care centre in Bhubaneswar

Background: Multidrug resistance has emerged as a challenge in health care settings. Again increasing prevalence of multidrug resistant (MDR), extensively drug resistant (XDR) and pan drug resistant (PDR) gram negative bacteria is making the condition more critical because of limited options of antibiotics, increasing morbidity, mortality and hospital stay of the patients. The present study is carried out with an aim to estimate the prevalence of MDR, XDR, PDR gram negative bacteria in a tertiary care hospital.Methods: Total of 912 gram negative bacterial isolates obtained from various samples of indoor patients in a tertiary care hospital, were studied over a period of six months. The bacteria were identified by conventional methods. Antibiotic sensitivity testing was done by Kirby Bauer disc diffusion method. Minimum inhibitory concentration (MIC) of antibiotics for the resistant isolates were detected by Vitek-2 automated method. MDR, XDR and PDR were determined according to the definitions suggested by European Centre for Disease Prevention and Control (ECDC), and Centers for Disease Control and Prevention (CDC). Prevalence of extended spectrum beta lactamase (ESBL) producers was estimated.Results: Out of 912 isolates, prevalence of MDR, XDR and PDR were 66.12%, 34.32% and 0.98% respectively. Prevalence of MDR and XDR were higher in ICUs than clinical wards (p<0.0001). Prevalence of ESBL producers was 48.4%.Conclusions: The study highlights increased prevalence of multidrug resistant and extensively drug resistant strains in our hospital. Stringent surveillance, proper implementation of hospital infection control practices and antimicrobial stewardship will help in limiting the emergence and spread of drug resistant strains.

Membrane permeabilization of colistin toward pan-drug resistant Gram-negative isolates

Abstract Pan-drug resistant Gram-negative bacteria, being resistant to most available antibiotics, represent a huge threat to the medical community. Colistin is considered the last therapeutic option for patients in hospital settings. Thus, we were concerned in this study to demonstrate the membrane permeabilizing activity of colistin focusing on investigating its efficiency toward those pan-drug resistant isolates which represent a critical situation. We determined the killing dynamics of colistin against pan-drug resistant isolates. The permeability alteration was confirmed by different techniques as: leakage, electron microscopy and construction of an artificial membrane model; liposomes. Moreover, selectivity of colistin against microbial cells was also elucidated. Colistin was proved to be rapid bactericidal against pan-drug resistant isolates. It interacts with the outer bacterial membrane leading to deformation of its outline, pore formation, leakage of internal contents, cell lysis and finally death. Furthermore, variations in membrane composition of eukaryotic and microbial cells provide a key for colistin selectivity toward bacterial cells. Colistin selectively alters membrane permeability of pan-drug resistant isolates which leads to cell lysis. Colistin was proved to be an efficient last line treatment for pan-drug resistant infections which are hard to treat.

Pharmaceutical Care for a Case of Pan-drug Resistant Acinetobacter baumannii Pulmonary Infection / 中国药房

OBJECTIVE:To explore the role of clinical pharmacists in the treatment of pan-drug resistant Acinetobacter bau-mannii infection. METHODS:Clinical pharmacists participated in the treatment for a severe pneumonia case of pan-drug resistant A. baumannii infection. Clinical pharmacists supplied overall pharmaceutical care and suggestions with respects to initial medication scheme evaluation,pathogen judgment,therapy drug selection,ADR disposal,etc.,including anti-infective treatment of moxifloxa-cin 0.4 g,ivgtt,qd+meropenem 0.5 g,ivgtt,q8 h+linezolid 0.6 g,ivgtt,q12 h;anti-pan-drug resistant A. baumannii infection of cefoperazone sodium and sulbactam sodium 3.0 g,ivgtt,q8 h+tigecycline 50 mg,ivgtt,q12 h;liver protection of ademetionine 1, 4-Butanedisulfonate 1.0 g,ivgtt,qd+reduced glutathione 1.8 g,ivgtt,qd. RESULTS:After 25 d treatment,the patient hadn’t been fe-vered,and hemogram and hepatic function index decreased to normal value. CONCLUSIONS:Clinical pharmacist should be en-gage in anti-infective treatment and pharmaceutical care,and provide physicians reasonable medication suggestion so as to promote care rate in the clinic.

Susceptibilidad antimicrobiana en Chile 2012 / Antimicrobial susceptibility in Chile 2012

Bacteria antimicrobial resistance is an uncontrolled public health problem that progressively increases its magnitude and complexity. The Grupo Colaborativo de Resistencia, formed by a join of experts that represent 39 Chilean health institutions has been concerned with bacteria antimicrobial susceptibility in our country since 2008. In this document we present in vitro bacterial susceptibility accumulated during year 2012 belonging to 28 national health institutions that represent about 36% of hospital discharges in Chile. We consider of major importance to report periodically bacteria susceptibility so to keep the medical community updated to achieve target the empirical antimicrobial therapies and the control measures and prevention of the dissemination of multiresistant strains.

La resistencia bacteriana es un problema de salud pública que lejos de estar controlado, aumenta en cantidad y complejidad. El Grupo Colaborativo de Resistencia, es un conjunto de profesionales que representan a 39 establecimientos de salud del país y que se ha ocupado desde 2008 de recolectar información sobre la susceptibilidad antimicrobiana de bacterias en Chile. En este documento se presenta la susceptibilidad in vitro acumulada del año 2012, de 28 establecimientos de salud del país que representan, al menos, 36% de los egresos hospitalarios de Chile. Consideramos de la mayor relevancia reportar periódicamente la susceptibilidad bacteriana de modo de mantener a la comunidad médica actualizada para orientar las terapias empíricas y las medidas de control y prevención de la diseminación de cepas multi-resistentes.

Monitoring and control of pan-drug resistant Acinetobacter baumannii colonization and infection in a medical intensive care unit / 中华危重病急救医学

Objective To describe the monitoring and control of pan-drug resistant Acinetobacter baumannii (XDRABA) colonization and infection in a medical intensive care unit (ICU),and to summarize the effective measures of surveillance of nosocomial infection and control.Methods Nonsurgical patients admitted to medical ICU of Peking University People's Hospital from September 2009 to April 2013 with length of ICU stay over 48 hours were surveyed.Number of cases of colonization and infection of XDRABA per month was recorded,and the clinical features of patients with XDRABA colonization and infection were observed.The control of XDRABA colonization and infection was divided into three stages:① Outbreak stage,from September 2009 to August 2010,the infection control measures included stringent hand hygiene and surface disinfection,use of disposable ventilator tubes and improvement in antibiotics use.② Environmental control stage,from September 2010 to April 2012,the infection control measures consisted of on-the-spot investigation,isolation of patients with XDRABA colonization and infection,tubes terminal environment disinfection.③ Microbial screening stage,from May 2012 to April 2013,throat,nose and axillary swabs were obtained when the patients admitted.Results From 2009 September to 2013 April there was a total of 193 patients colonized or infected with XDRABA,and 64 patients died (mortality rate was 33.2％),and 133 (68.9％) patients were on mechanical ventilation.Patients with XDRABA colonization and infection had severer illness [acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score 20.3 ±6.7],longer ICU stay [(34.6 ± 13.8) days].In outbreak stage,number of cases with XDRABA colonization and infection was 5-9 per month.In environmental control stage,case number of XDRABA colonization and infection was 3-6 per month.In microbial screening stage,case number of XDRABA colonization and infection,which were already present,was 2-4 per month,and they were mainly admitted from emergency department (59.5％).The number of cases of ICU acquired XDRABA colonization and infection decreased from 2-3 to 0-1 per month.Conclusion To control the colonization and infection of XDRABA,monitoring of microorganism,hand hygiene,isolation of patients with XDRABA colonization and infection,and stringent environment disinfection were very necessary.

In vitro activities of Minocycline and polymycin B against pan-drug resistant Acinetobacter baumanii / 国际检验医学杂志

Objective To investigate the in vitro susceptibility of Minocycline and polymycin B against clinical islates of pan-drug resistant Acinetobacter baumanii ,to provide laboratory support for clinical treatment for drug selection.Methods The susceptible test of Minocycline and polymycin against 39 isolates of pan-drug resistant Acinetobacter baumanii were determined by K-B meth-od.Results 38 strains of pan-resistant Acinetobacter baumanii were sensitive to polymyxin B,sensitive rate was 97.4%,20 strains sensitive to minocycline,the sensitivity rate was 51.3%.polymyxin B sensitivity was more sensitive than Minocycline (P < 0.05). Conclusion Polymycin B had strong activit ies against pan-drug resistant Acinetobacter baumanii .

Study on the anti-bacteria effects of polymyxin B combined with meropenem against pan-drug-resistant pseudomonas aeruginosa / 中国生化药物杂志

Objective To evaluate the anti-bacteria effects of polymyxin B combined with meropenem against 30 strains pan-drug resistant pseudomonas aeruginosa that separated in clinic. Methods The minimal inhibitory concentration (MICs) of 30 strains pan-drug resistant pseudomonas aeruginosa after treated with polymyxin B and meropenem as single-use or combination use were determined by both microdilution method and checkerboard method. The FIC index was calculated, then the type of combination effect was determined according to FIC index, which was used to determine whether there was synergistic or antagonistic effects. Results The MICs of pan-drug resistant pseudomonas aeruginosa were reduced significantly after polymyxin B combined with meropenem when compared with single-use. The percentages of the FIC index that less than 0.5 and the index between 0.5 and 1 were 60%and 30%respectively. Conclusion The results indicate that the combinations of polymyxin B with meropenem have good synergistic and additive effects against pan-drug resistant pseudomonas aeruginosa, there is no antagonism.

The situation of drug resistant bacterial infection in the intensive care unit of the first central state hospital, Mongolia / Монголын Анагаах Ухаан

INTRODUCTION: Sepsis is always a serious, life-threatening condition, with high mortality rate varying from 30-50% (40-70% in septic shock) in the developed countries, and in developing countries as well. Antibiotic resistance is an important factor in sepsis management. GOAL: To evaluate the resistance patterns of microorganisms, to analyze the correlation between outcome of sepsis patient and multidrug resistant bacterial infection. MATERIALS AND METHODS: This study was designed as a prospective observational study and conducted in a nine bed multidisciplinary intensive care unit (ICU) of a tertiary teaching hospital in Ulaanbaatar, during January 2011 - August 2012. The ICU treatment outcome and length of stay were compared between the patient groups which infected by resistant and non-resistant bacteria. RESULTS: The positive rate of extensively resistant (XDR) and multi drug resistant bacteria by culture test were 22% and 25.1%, respectively. Fifty one percent of sepsis patients were infected by one or more resistant bacteria. Bacteria with an exceptionally high rate of antibiotic resistance (≥60%) were Acinetobacter baumannii, Enterobacter spp and coagulase-negative Staphylococci. Sepsis patients who were infected with resistant bacteria received more mechanical ventilation, renal replacement therapy and suffered from multiple organ dysfunctions when compared to sepsis patients with nonresistant bacterial infection. The length of stay in the ICU was longer in sepsis patients with resistant bacteria but the mortality rate in the ICU did not significantly differ between groups. However, a higher fatality rate was noted in sepsis patients infected with resistant bacteria. In conclusion, resistant bacteria were detected in up to 50% of microbiological samples from critically ill sepsis patients in the ICU of a tertiary teaching hospital in Ulaanbaatar. Antibiotic resistance appears to be a relevant problem of sepsis management in a Mongolian ICU setting.

The clinical effect of cefoperazone sulbactam associated with tigecycline on pulmonary infection caused by pan drug-resistant Acinetobacter baumannii / 中国中西医结合急救杂志

Objective To approach the clinical effect of cefoperazone sulbactam associated with tigecycline for treatment of patients with severe pulmonary infection caused by pan drug-resistant Acinetobacter baumannii in intensive care unit(ICU). Methods Retrospectively,the treatments of 88 patients with sepsis and pulmonary infection caused by pan drug-resistant Acinetobacter baumannii admitted in ICU from January,2011 to June,2013 were analyzed,among them antibiotics were used for 82 patients,and the rest 6 patients did not use antibiotics because of family refusal or abandonment of therapy. The patients having used antibiotics were divided into three groups:A group(27 patients)received cefoperazone sulbactam,B group(30 patients)received cefoperazone sulbactam associated with amikacin,and C group(25 patients)received cefoperazone sulbactam associated with tigecycline, antimicrobial treatment being for 7-15 days. The venous blood was collected to determine the changes in white blood cell count(WBC),C-reactive protein(CRP)and procalcitonin(PCT)before and after therapy. The rate of bacteriological efficiency,successful weaning of mechanical instrument,28-day mortality rate and clinical efficacy were observed after therapy in three groups. Results Before therapy,the comparisons of levels of WBC,CRP and PCT among three groups were of no statistically significant difference(all P>0.05),and they were decreased obviously after therapy in three groups among which they were decreased most significantly in C group〔WBC(×109/L):17.01±5.35 vs. 20.40±6.54,18.28±6.41;CRP(mg/L):64.6±8.4 vs. 68.3±12.7,70.0±13.4;PCT(μg/L):20.84±7.26 vs. 36.14±10.12,52.66±13.47,P<0.05〕. The rates of bacteriological efficiency and successful weaning in C group were increased more significantly than those in either A or B groups after therapy(bacteriological efficiency:76.00%vs. 44.44%,46.67%,χ2=9.750,P=0.006;rate of successful weaning:72.00%vs. 40.74%, 43.33%,χ2=12.083,P=0.009),and 28-day mortality rate in C group was much lower than those in A and B groups (24.00% vs. 48.15%,36.67%,χ2=11.510,P=0.030). The total clinical efficiency in C group was much higher than those in A and B groups(76.00%vs. 44.44%,46.67%,both P<0.05). Conclusion Cefoperazone sulbactam associated with tigecycline has significant clinical therapeutic effect in patients with pulmonary infection caused by pan drug-resistant Acinetobacter baumannii in ICU,as it can decrease inflammatory reaction,increase the rates of successful weaning and survival.

Combined antimicrobial susceptibility test against pan-drug-resistant Acinetobacter baumannii with E-test and microdilution checkerboard assay / 中华微生物学和免疫学杂志

Objective To evaluate the activity of antibiotics against pan-drug-resistant (PDR) Acinetobacter baumannii by combination antimicrobial susceptibility test in viro with epsilometric methods (Etest method) and microdilution checkerboard (CB method),and to detect a good correlation between timekill curve with the above mentioned two assays.Methods Thirty-one clinical isolates of PDR Acinetobacter baumannii were selected for mono and combination antimicrobial susceptibility test in vitro by E-test and CB method,then a comparison was conducted between the test results and the time-kill curve.Mono drugs involved tigecycline,colistin,imipenem and amikacin,and combinations involved two of drugs above,and three drugs involved imipenem/tigecycline,plus amikacin combination.Results Synergistic effect was detected in imipenem plus colistin and tigecycline plus imipenem combination.A high comparability was revealed between the E-test method with antimicrobial drugs added into the culture medium and the time-kill curves.Synergy in the combination of imipenem/tigecycline,plus amikacin was detected by the CB method and time-kill curves.Conclusion The results showed that the effect of specific combination of antibiotics against PDR Acinetobacter baumannii could be predicted by testing their synergistic effect with combination antimicrobial susceptibility test.

Genes of ?-Lactamase in Pan-drug Resistant Pseudomonas aeruginosa and Phylogenetic Analysis / 中华医院感染学杂志

OBJECTIVE To investigate the presence of ?-lactamase genes in pan-drug resistant Pseudomonas aeruginosa (PDRPA),and the redateness in PDRPA. METHODS The genes of 21 kinds of resistance were detected by polymerase chain reaction and phylogenetic analysis. RESULTS In 33 strains of PDRPA,the positive rates of blaTEM,blaOXA-10cluster,blaPER,blaGES,blaCARB,intⅠ1 and merA were 48.5%,45.5%,33.3%,21.2%,15.2%,78.8% and 69.7%,respectively. There were clone transmitted phenomena. CONCLUSIONS There are very high positive percentages of blaTEM,blaOXA-10cluster,blaPER,blaGES,blaCARB,intⅠ1 and merA genes in PDRPA. The PDRPA can induce clone transmitted hospital infection.

Prevention and Treatment Policy of Pan-drug Resistant Bacteria for Surgical Critical Patients / 中华医院感染学杂志

OBJECTIVE To investigate the distribution scope of the pan-drug resistant bacteria in the SICU patients including their producing environment and high risk factors in these two years and to approach its prevention and treatment policy. METHODS The distribution scope and the high risk factors of the pan-drug resistant bacteria in SICU were reviewed and analyzed from Jan 2005 to Jan 2007.RESULTS There were 11 cases in the period from Jan 2005 to Jan 2006; and was only 1 case from Jan 2006 to Jan 2007. CONCLUSIONS To establish the drug resistance monitoring system, attach great importance to isolation and education, to monitor the original region of the pan-drug resistant bacteria, and to adopt the comprehensive antibiotic policy to control the drug resistant bacteria. Among them, the early effective isolation of high risk patients may be very effective to reduce the producing and developing of the pan-drug resistant bacteria.

Study on the Genotyping of Aminoglycoside Modifying Enzymes Genes from Pan-drug Resistant Acinetobacter Baumannii / 医学研究杂志

Objective To investigate the genotyping of aminoglycoside modifying enzymes on Pan-drug resistant A..baumannii(PDRA)isolated.Methods The antibiotic susceptibility of 16 different antibiotics of A.baumannii were tested by K-B method,aminoglycoside modifying enzymes coding genes of A.baumannii were detected by PCR.Results The detection rates of OXA-23group were 41.8%and aminoglycoside modifying enzymes coding genes of aac(3)-Ⅰ,aac(6')-Ⅰand ant(3″)-Ⅰ were 64.1%,64.1% and 74.4%.Conclusions The study showed that it is more serious for PDRA carrying aminoglycoside modifying enzymes coding genes.

Determination of Genomospecies and Characterization of Antimicrobial Resistance of Multi-drug Resistant Acinetobacter spp. Isolates

Acinetobacter species are non-fermentative Gram-negative coccobacilli and they have emerged as important nosocomial pathogens which are associated with the significant multidrug resistance in recent years. Carbapenem-resistant A. baumannii (CRAB) and pandrug-resistant A. baumannii (PDRAB) were reported in 1991 and 1998, respectively. Fiftyeight isolates of Acinetobacter species recovered from a university hospital between August 2004 and March 2005 were investigated for the existence of CRAB, PDRAB, extended-spectrum beta-lactamase (ESBL)-producing Acinetobacter and examined for their phenotypic and genotypic characteristics. Genomospecies of Acinetobacter species were determined by amplified rDNA restriction analysis (ARDRA) and antimicrobial susceptibility test was performed with 13 kinds of antimicrobial agents. Metallo-beta-lactamase (MBL) producers were screened by modified hodge test and confirmed by imipenem-EDTA disk synergy test. Detection of blaIMP-1, blaVIM-2, blaTEM, and blaPER-1 was performed by PCR. Genomic DNAs were analyzed by pulsed-field gel electrophoresis (PFGE). Among 58 isolates of Acinteobacter species, 40 isolates were identified as genospecies 2 (A. baumannii), 9 were 13TU, 5 were A. phenon 6/ct, and 4 were Acinetobacter genospecies 3 by ARDRA. Thirteen isolates were confirmed as MBL-producers and blaIMP-1 and blaVIM-2 were carried by 5 and 8 isolates of them, respectively. MBL-producers were mostly 13TU, A. phenon 6/ct 13TU, and Acinetobacter genospecies 3 and they were susceptible to ciprofloxacin and ampicillin-sulbactam. BlaPER-1 was carried by thirteen isolates and 12 isolates of them were PDRAB showing resistance to all antimicrobial agents tested, including ceftazidime, cefepime, aztreonam, ciprofloxacin, amikacin, gentamicin, ampicillin-sulbactam, and imipenem. In conclusion, most MBL-producers belonged to 13TU, A. phenon 6/ct 13TU, and Acinetobacter genospecies 3 which were susceptible to ciprofloxacin and ampicillin-sulbactam, whereas 12 of 13 PER-1-producers were PDRAB originated from the same clone.

Determination of Genomospecies and Characterization of Antimicrobial Resistance of Multi-drug Resistant Acinetobacter spp. Isolates

Acinetobacter species are non-fermentative Gram-negative coccobacilli and they have emerged as important nosocomial pathogens which are associated with the significant multidrug resistance in recent years. Carbapenem-resistant A. baumannii (CRAB) and pandrug-resistant A. baumannii (PDRAB) were reported in 1991 and 1998, respectively. Fiftyeight isolates of Acinetobacter species recovered from a university hospital between August 2004 and March 2005 were investigated for the existence of CRAB, PDRAB, extended-spectrum beta-lactamase (ESBL)-producing Acinetobacter and examined for their phenotypic and genotypic characteristics. Genomospecies of Acinetobacter species were determined by amplified rDNA restriction analysis (ARDRA) and antimicrobial susceptibility test was performed with 13 kinds of antimicrobial agents. Metallo-beta-lactamase (MBL) producers were screened by modified hodge test and confirmed by imipenem-EDTA disk synergy test. Detection of blaIMP-1, blaVIM-2, blaTEM, and blaPER-1 was performed by PCR. Genomic DNAs were analyzed by pulsed-field gel electrophoresis (PFGE). Among 58 isolates of Acinteobacter species, 40 isolates were identified as genospecies 2 (A. baumannii), 9 were 13TU, 5 were A. phenon 6/ct, and 4 were Acinetobacter genospecies 3 by ARDRA. Thirteen isolates were confirmed as MBL-producers and blaIMP-1 and blaVIM-2 were carried by 5 and 8 isolates of them, respectively. MBL-producers were mostly 13TU, A. phenon 6/ct 13TU, and Acinetobacter genospecies 3 and they were susceptible to ciprofloxacin and ampicillin-sulbactam. BlaPER-1 was carried by thirteen isolates and 12 isolates of them were PDRAB showing resistance to all antimicrobial agents tested, including ceftazidime, cefepime, aztreonam, ciprofloxacin, amikacin, gentamicin, ampicillin-sulbactam, and imipenem. In conclusion, most MBL-producers belonged to 13TU, A. phenon 6/ct 13TU, and Acinetobacter genospecies 3 which were susceptible to ciprofloxacin and ampicillin-sulbactam, whereas 12 of 13 PER-1-producers were PDRAB originated from the same clone.

Genes of 16S rRNA Methylase and Aminoglycoside-modifying Enzymes in Pan-drug Resistant Pseudomonas aeruginosa / 中华医院感染学杂志

OBJECTIVE To investigate mechanisms of aminoglycoside resistance in pan-drug resistant Pseudomonas aeruginosa(PDRPA).METHODS The 11 genes of 16S rRNA methylase and aminoglycoside-modifying enzymes were detected by polymerase chain reaction(PCR) and verified by DNA sequencing.RESULTS In 33 strains of PDRPA,the positive rates of rmtB,aac(3)-Ⅱ,aac(6′)-Ⅰb,aac(6′)-Ⅱ,ant(3″)-Ⅰ and ant(2″)-Ⅰ were 42.4%,51.5%,42.4%,57.6%,48.5% and 63.6%.A total of 32 strains identified aminoglycoside modified genes,one strain aminoglycoside-modifying enzyme gene did not discovered,but rmtB positive.CONCLUSIONS The aminoglycoside resistance mechanisms of the PDRPA are the production of 16S rRNA methylase and aminoglycoside-modifying enzymes related.

Let us understand clinical outcome in surveillance of resistance of bacteria / 中华检验医学杂志

It is an important task to lab of clinical microbiology to surveille multi-drag or pan-drug resistant strains,such as penicillin-or macrolide-resistant Streptococcus pneumoniae,methicillin-resistant Staphylococcus aureus(MRSA),3rd generation cephalosporin-or quinolone-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii,and so on.We must understand characteristics of these resistant strains to guide doctors' empirical therapy of infective diseases.